What assay supports the specificity label for type II-D Cas9?
Efficiency at the intended locus does not establish specificity. For each compact type II-D Cas9, the evidence should resolve the full intended-site product distribution, nearby bystander edits and candidate or genome-wide off-target events, including larger structural changes. What assay combination, controls and detection limits support each category, and were low-frequency outcomes validated with an orthogonal method?
